CPL976-MMAE / Celon Pharma - LARVOL DELTA

Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ ant-AXL antibody with a dual mechanism of action (AACR 2024) - "We presented a new, ADC based on bispecific anti-PD-L1/anti-AXL antibody conjugated with MMAE, that combines the effects of cancer growth inhibition by interaction with AXL and immunotherapy by disruption of the PD-1/PD-L1 axis, with selective delivery of MMAE to cancer cells. The simultaneous action of delivering the toxin and acting on both therapeutic targets provides a potent synergistic anti-tumor effect, that can lead to complete tumor eradication and potentially overcome the primary and secondary resistance to PD-1/PD-L1 targeted therapies."

IO biomarker • Oncology • AXL